A COhort Study on Factors Leading to Vulnerability in Adult Patients With Serious Medical cOnditionS: the COSMOS-I Trial

NCT07740239 | Recruiting

• 1 other identifier: R24006
• Study Type: observational
• Target: 2,050
• Locations: 1 country
• Sites: 1

Brief Summary

The objective of this prospective multicentre study that recruits altogether 1500 older patients from the university hospitals of Tampere, Kuopio, and Oulu is to explore the clinical significance and detection of causes of generalized vulnerability. The objectives are: O1 - Establish the prevalence of causes of generalized vulnerability among patients diagnosed with severe yet non-malignant diseases and local/locally advanced and advanced cancers, O2 - Study how causes of generalized vulnerability affect the time between the diagnosis and the adoption of a fully palliative treatment line, overall survival, and patient-reported quality of life in older adults severe diseases, and O3 - Evaluate how screening tools commonly used in patients without cancer perform in screening for causes of vulnerability in older adults with cancer

Conditions

Pelvic Fracture; Prostate Cancer; Lung Cancer; Brain Metastasis; Chronic Subdural Hematoma

Outcome Measures

Primary Outcomes (1)

• Detected cause of vulnerability

  Around the time of study procedure

Study Arms (6)

Prostate Cancer

Other: Test set to determine vulnerability

Lung Cancer

Other: Test set to determine vulnerability

Pelvic Fracture

Other: Test set to determine vulnerability

Chronic Subdural Hematoma

Other: Test set to determine vulnerability

Brain Metastasis

Other: Test set to determine vulnerability

High-dose Chemotherapy and Stem Cell Transplant

Other: Test set to determine vulnerability

Interventions

Test set to determine vulnerability OTHER

This is a prospective observational study.

Brain Metastasis; Chronic Subdural Hematoma; High-dose Chemotherapy and Stem Cell Transplant; Lung Cancer; Pelvic Fracture; Prostate Cancer

Eligibility Criteria

• Sex: male
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

* Patients with local, locally advanced and metastatic prostate cancer (n=300) * Patients with locally advanced and metastatic lung cancer (n=300) * Patients with brain metastasis (n=300) * Patients with chronic subdural hematoma (n=300) * Patients receiving high-dose chemotherapy and stem cell transplantion

You may qualify if:

• Suspected or diagnosed disease
• ≥60 years old patients, except for patients receiving high-dose chemotherapy and stem cell transplantion who need to be ≥18 years old
• Cross-sectional imaging maximum 45 days prior to consenting or before the next treatment line
• Patients with cancer (other than patients with prostate cancer treated with hormonal treatment before radiation treatment): study procedures (excluding image analyses) must have been carried out maximum 1 month prior to the start of a new treatment line
• Patients with prostate cancers receiving hormonal treatment before radiation treatment): study procedures (excluding image analyses) must be carried out maximum 3 months after the start of hormonal treatment
• Patients with other conditions: study procedures (excluding image analyses) must have been carried out maximum 4 days after the start of the hospitalization

You may not qualify if:

• Not willing or unable to give written consent
• Patient not deemed suitable for the study by the researcher approaching the patient

Sponsors & Collaborators

• Tampere University Hospital: lead

Study Sites (1)

Tampere University Hospital

Tampere, Finland

RECRUITING

MeSH Terms

Conditions

Hip Fractures; Prostatic Neoplasms; Lung Neoplasms; Brain Neoplasms; Hematoma, Subdural, Chronic

Condition Hierarchy (Ancestors)

Femoral Fractures; Fractures, Bone; Wounds and Injuries; Hip Injuries; Leg Injuries; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases; Respiratory Tract Neoplasms; Thoracic Neoplasms; Lung Diseases; Respiratory Tract Diseases; Central Nervous System Neoplasms; Nervous System Neoplasms; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Hematoma, Subdural; Intracranial Hemorrhage, Traumatic; Intracranial Hemorrhages; Cerebrovascular Disorders; Craniocerebral Trauma; Trauma, Nervous System; Vascular Diseases; Cardiovascular Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Hematoma; Hemorrhage

Central Study Contacts

Otso Arponen, Adjunct professor, MD

CONTACT

504106170; otso.arponen@tuni.fi

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Adjunct professor, MD

Study Record Dates

• First Submitted: July 28, 2026
• First Posted: July 31, 2026
• Study Start: November 13, 2024
• Primary Completion (Estimated): December 30, 2030
• Study Completion (Estimated): December 30, 2030
• Last Updated: July 31, 2026

Record last verified: 2026-07

Locations

FI (1)